MC46 peptide

CAT:
804-HY-P10801
Size:
1 Each
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
MC46 peptide - image 1

MC46 peptide

  • Description:

    MC46 (C46) peptide is a membrane-associated fusion peptide inhibitor. mC46 peptide potently inhibits HIV-1 replication and entry. mC46 also inhibits CCR5-tropic, CXCR4-tropic, and dual-tropic HIVs, SIV, and SHIV[1].
  • Product Name Alternative:

    C46 peptide
  • UNSPSC:

    12352209
  • Target:

    HIV
  • Related Pathways:

    Anti-infection
  • Field of Research:

    Infection
  • Smiles:

    O=C([C@@H](N)CC1=CNC2=CC=CC=C12)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(O)=O)CC3=CC=CC=C3)=O)CC4=CNC5=CC=CC=C45)=O)CC(N)=O)=O)CC6=CNC7=CC=CC=C67)=O)CC(C)C)=O)CO)=O)C)=O)CC8=CNC9=CC=CC=C89)=O)CCCCN)=O)CC(O)=O)=O)CC(C)C)=O)CCC(O)=O)=O)CC(C)C)=O)CC(C)C)=O)CCC(O)=O)=O)CCC(N)=O)=O)CCC(O)=O)=O)CC(N)=O)=O)CCCCN)=O)CCC(O)=O)=O)CCC(N)=O)=O)CCC(N)=O)=O)CC(N)=O)=O)CCC(N)=O)=O)CO)=O)CCC(O)=O)=O)CCC(O)=O)=O)[C@H](CC)C)=O)CC(C)C)=O)CO)=O)CC%10=CNC=N%10)=O)[C@H](CC)C)=O)CC(C)C)=O)CO)=O)[C@@H](C)O)=O)CC%11=CC=C(O)C=C%11)=O)CC(N)=O)=O)CC(N)=O)=O)[C@H](CC)C)=O)CCC(O)=O)=O)CCCNC(N)=N)=O)CC(O)=O)=O)CC%12=CNC%13=CC=CC=C%12%13)=O)CCC(O)=O)=O)CCSC
  • Molecular Formula:

    C263H381N67O82S
  • Molecular Weight:

    5825.30
  • References & Citations:

    [1]Delviks-Frankenberry KA, et al. Potent dual block to HIV-1 infection using lentiviral vectors expressing fusion inhibitor peptide mC46- and Vif-resistant APOBEC3G. Mol Ther Nucleic Acids. 2023 Aug 11;33:794-809.
  • Shipping Conditions:

    Room temperature
  • Scientific Category:

    Peptides
  • Clinical Information:

    Phase 2